Open AccessOridonin Inhibits SARS‐CoV‐2 by Targeting Its 3C‐Like Protease
Author(s) -
Zhong Baisen,
Peng Weiyu,
Du Shan,
Chen Bingyi,
Feng Yajuan,
Hu Xinfeng,
Lai Qi,
Liu Shujie,
Zhou Zhong-Wei,
Fang Pengfei,
Wu Yan,
Gao Feng,
Zhou Huihao,
Sun Litao
Publication year - 2022
Publication title -
small science
Language(s) - English
Resource type - Journals
ISSN - 2688-4046
DOI - 10.1002/smsc.202270012
Subject(s) - protease , natural product , covid-19 , neuroprotection , pharmacology , chemistry , virology , biology , enzyme , medicine , biochemistry , disease , pathology , infectious disease (medical specialty)
Oridonin Inhibits SARS‐CoV‐2 Oridonin, a natural product extracted from Rabdosia rubescens , possesses a wide range of pharmacological properties, including anti‐inflammatory, anti‐cancer, anti‐microbial, neuroprotection, immunoregulation, etc. In article number 2100124 , Baisen Zhong, Litao Sun, and co‐workers demonstrate that Oridonin targets the SARS‐CoV‐2 3CL protease by covalently binding to cysteine145 in its active pocket to exert an anti‐SARS‐CoV‐2 effect, which provides a novel candidate for the treatment of COVID‐19.